Similarly, in the soleus muscle, the treatment with FGF19 also counteracted the CKD-induced defects in muscle fiber size, with a reduction of the number of small myofibers and an increase of myofibers within the range 1200–2200 μm2 (Fig. 2G–K). This evidence concerns the gene FGF19 and chronic kidney disease.